Programs

Mucosis’s lead program SynGEM® seeks to develop a new mucosal vaccines to prevent respiratory syncytial virus vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against RSV in vulnerable people, such as elderly and children. Mucosis also runs research programs aimed at the development of mucosal vaccines to prevent pneumococcal related diseases, and an oral vaccine to prevent bacterial diarrhea (shigella/etec).  These programs build upon the success of the Mucosis FluGEM® which achieved proof-of-concept for the Mimopath platform.

The development phases of the Mucosis programs

research programs

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >

30.09.14 Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum
more >

22.05.14 Mucosis receives financial support from the Dutch government for its SynGEM® program
more >